Stock listing
NASDAQ:LUCD Lucid Diagnostics Inc. Stock
Home listing (NASDAQ) of Lucid Diagnostics Inc.
Follow Lucid Diagnostics Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:LUCD
$0.373 USD -0.035 (-8.6%)
Close on Nov 20, 2026
- Day range
- $0.355 – $0.395 USDNov 20, 2026
- Volume
- 2.26M sharesNov 20, 2026
- Market cap
- $77.14M USDAt the close on Nov 20, 2026 · price × 207.0M shares outstanding
- 52-week range
- $0.303 – $1.629 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.37M USDMedian day 1.64M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:LUCD · Home | $0.373 USD | -0.035 (-8.6%) | 2,261,958 | $0.380 | $0.395 | $0.355 | $0.408 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LUCD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.373 | -0.035 | -8.6% | $0.380 | $0.395 | $0.355 | 2,261,958 | |
| $0.408 | +0.009 | +2.2% | $0.405 | $0.417 | $0.372 | 2,703,842 | |
| $0.399 | +0.001 | +0.3% | $0.400 | $0.404 | $0.370 | 2,149,543 | |
| $0.398 | -0.051 | -11.4% | $0.458 | $0.465 | $0.391 | 2,169,849 | |
| $0.449 | +0.033 | +7.9% | $0.444 | $0.492 | $0.423 | 3,460,638 | |
| $0.416 | +0.035 | +9.2% | $0.400 | $0.430 | $0.383 | 2,358,379 | |
| $0.381 | -0.019 | -4.7% | $0.410 | $0.420 | $0.373 | 1,740,179 | |
| $0.400 | -0.017 | -4.2% | $0.423 | $0.430 | $0.395 | 1,386,685 | |
| $0.418 | +0.019 | +4.9% | $0.395 | $0.426 | $0.395 | 1,644,978 | |
| $0.398 | +0.008 | +2.0% | $0.387 | $0.401 | $0.385 | 1,262,773 | |
| $0.390 | -0.055 | -12.4% | $0.449 | $0.449 | $0.390 | 2,026,558 | |
| $0.445 | +0.036 | +8.8% | $0.411 | $0.478 | $0.407 | 3,548,164 | |
| $0.409 | +0.003 | +0.7% | $0.400 | $0.434 | $0.396 | 1,613,909 | |
| $0.406 | +0.002 | +0.4% | $0.405 | $0.411 | $0.393 | 1,333,060 | |
| $0.405 | -0.028 | -6.4% | $0.415 | $0.440 | $0.403 | 1,706,040 | |
| $0.432 | +0.021 | +5.0% | $0.412 | $0.456 | $0.403 | 5,052,427 | |
| $0.412 | -0.026 | -6.0% | $0.438 | $0.440 | $0.380 | 6,315,332 | |
| $0.438 | -0.063 | -12.5% | $0.520 | $0.546 | $0.415 | 10,226,161 | |
| $0.501 | +0.090 | +21.8% | $0.416 | $0.560 | $0.406 | 43,499,882 | |
| $0.411 | +0.083 | +25.4% | $0.434 | $0.453 | $0.388 | 111,802,493 | |
| $0.328 | -0.006 | -1.7% | $0.321 | $0.330 | $0.303 | 48,099,609 | |
| $0.333 | -0.019 | -5.3% | $0.360 | $0.393 | $0.321 | 3,688,715 | |
| $0.352 | -0.026 | -6.8% | $0.368 | $0.375 | $0.303 | 6,330,013 | |
| $0.377 | -0.101 | -21.0% | $0.480 | $0.480 | $0.358 | 4,274,411 | |
| $0.478 | -0.042 | -8.1% | $0.522 | $0.526 | $0.470 | 2,335,027 | |
| $0.520 | -0.023 | -4.2% | $0.544 | $0.569 | $0.510 | 3,007,774 | |
| $0.543 | -0.063 | -10.4% | $0.591 | $0.618 | $0.540 | 1,818,047 | |
| $0.606 | +0.009 | +1.4% | $0.600 | $0.620 | $0.577 | 1,096,500 | |
| $0.597 | -0.041 | -6.4% | $0.632 | $0.660 | $0.597 | 1,635,460 | |
| $0.638 | -0.012 | -1.9% | $0.650 | $0.690 | $0.621 | 1,947,148 | |
| $0.650 | +0.027 | +4.3% | $0.610 | $0.674 | $0.603 | 2,509,163 | |
| $0.624 | +0.024 | +3.9% | $0.591 | $0.653 | $0.588 | 1,712,838 | |
| $0.600 | +0.007 | +1.1% | $0.600 | $0.611 | $0.580 | 1,458,836 | |
| $0.593 | -0.034 | -5.4% | $0.623 | $0.676 | $0.590 | 1,833,001 | |
| $0.627 | -0.008 | -1.2% | $0.635 | $0.675 | $0.625 | 2,255,357 | |
| $0.635 | -0.116 | -15.5% | $0.723 | $0.725 | $0.500 | 6,786,100 | |
| $0.751 | -0.058 | -7.2% | $0.815 | $0.815 | $0.740 | 1,776,965 | |
| $0.809 | +0.003 | +0.4% | $0.810 | $0.834 | $0.800 | 771,675 | |
| $0.806 | -0.020 | -2.5% | $0.820 | $0.827 | $0.803 | 786,366 | |
| $0.826 | -0.012 | -1.4% | $0.843 | $0.849 | $0.816 | 1,188,948 | |
| $0.838 | -0.001 | -0.1% | $0.834 | $0.877 | $0.820 | 1,132,937 | |
| $0.839 | -0.054 | -6.0% | $0.885 | $0.900 | $0.821 | 945,099 | |
| $0.893 | +0.047 | +5.6% | $0.855 | $0.907 | $0.832 | 1,525,367 | |
| $0.845 | +0.059 | +7.6% | $0.793 | $0.850 | $0.774 | 1,393,727 | |
| $0.786 | +0.005 | +0.7% | $0.800 | $0.800 | $0.766 | 2,402,878 | |
| $0.780 | -0.056 | -6.7% | $0.823 | $0.843 | $0.750 | 1,282,822 | |
| $0.836 | +0.043 | +5.4% | $0.787 | $0.844 | $0.777 | 1,274,214 | |
| $0.794 | +0.011 | +1.4% | $0.782 | $0.800 | $0.750 | 1,250,488 | |
| $0.783 | 0.000 | 0.0% | $0.779 | $0.798 | $0.774 | 958,674 | |
| $0.783 | -0.021 | -2.6% | $0.848 | $0.856 | $0.780 | 1,223,979 | |
| $0.804 | -0.017 | -2.1% | $0.830 | $0.830 | $0.789 | 1,254,414 | |
| $0.821 | -0.076 | -8.4% | $0.901 | $0.915 | $0.812 | 1,779,452 | |
| $0.897 | -0.043 | -4.5% | $0.935 | $0.935 | $0.891 | 964,588 | |
| $0.940 | -0.012 | -1.2% | $0.941 | $0.959 | $0.927 | 1,016,800 | |
| $0.951 | -0.039 | -3.9% | $0.984 | $0.989 | $0.940 | 837,646 | |
| $0.990 | +0.016 | +1.6% | $0.960 | $0.993 | $0.957 | 636,514 | |
| $0.974 | -0.005 | -0.5% | $0.970 | $0.999 | $0.962 | 449,013 | |
| $0.979 | -0.013 | -1.3% | $0.990 | $1.010 | $0.974 | 423,399 | |
| $0.991 | +0.007 | +0.8% | $0.985 | $1.000 | $0.972 | 426,794 | |
| $0.984 | +0.013 | +1.4% | $0.962 | $1.019 | $0.960 | 966,858 | |
| $0.971 | -0.039 | -3.9% | $1.000 | $1.015 | $0.960 | 834,240 | |
| $1.010 | +0.010 | +1.0% | $1.000 | $1.040 | $0.990 | 1,108,666 | |
| $1.000 | +0.036 | +3.7% | $0.968 | $1.020 | $0.951 | 645,664 | |
| $0.964 | +0.004 | +0.4% | $0.970 | $0.983 | $0.940 | 415,411 | |
| $0.960 | -0.050 | -4.9% | $0.999 | $1.010 | $0.958 | 980,470 |
- Ticker
- NASDAQ:LUCD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Latest earnings call · Nov 12, 2026
Lucid Diagnostics (NASDAQ:LUCD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 12, 2026
Q3 2026 Earnings Presentation
Earnings · 15 slides
Latest news
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Nov 12, 2026
Closed $0.416 (+9.2%) on Nov 12, 2026
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
Nov 5, 2026
Closed $0.39 (-12.4%) on Nov 5, 2026
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Nov 4, 2026
Closed $0.445 (+8.8%) on Nov 4, 2026
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
Nov 3, 2026
Closed $0.409 (+0.7%) on Nov 3, 2026
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
Oct 29, 2026
Closed $0.432 (+5.0%) on Oct 29, 2026
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Oct 22, 2026
Closed $0.411 (+25.4%) on Oct 23, 2026
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Sep 22, 2026
Closed $0.893 (+5.6%) on Sep 22, 2026
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Aug 13, 2026
Closed $0.965 (-2.0%) on Aug 13, 2026
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
Aug 5, 2026
Closed $1.00 (+4.3%) on Aug 5, 2026
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
Jul 30, 2026
Closed $0.901 (-1.9%) on Jul 30, 2026
Lucid Diagnostics Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 20 in the last 12 months · 128 in all · newest Nov 12, 2026 · oldest 2021
- Calls
- 20 calls with a replay · 20 with a transcript · latest Nov 12, 2026
- Decks
- 12 decks · latest Nov 12, 2026
Where Lucid Diagnostics Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:LUCD · Home listing · This page | NASDAQ | United States | USD |
| BOATS:LUCD | BOATS | United States | USD |
Valuation
EV/sales 14.3× against a median of 4.3×: 10th lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $77.63M USD
- P/E
- Loss
- EV/sales
- 14.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 13.0×
- Gross margin
- −20.6%
- Operating margin
- −941.7%
- Net margin
- −892.8%
- Debt to equity
- 3.1×
- Beta vs S&P 500
- 1.36
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lucid Diagnostics Inc. · NASDAQ:LUCD | US$77.14M | US$77.63M | n/a | 14.3× | n/a | 13.0× | −892.8% | 3.1× | 1.36 |
| Exagen Inc. · NASDAQ:XGN | US$92.10M | US$86.82M | n/a | 1.2× | n/a | 6.7× | −25.1% | 1.7× | 2.52 |
| Biodesix, Inc. · NASDAQ:BDSX | US$83.83M | US$105.4M | n/a | 1.0× | n/a | 9.7× | −25.7% | 5.8× | 1.56 |
| Bonraybio Co. Ltd. · TWSE:6955 | US$81.85M | US$65.60M | 25.0× | 6.5× | 18.1× | 4.1× | 32.5% | 0.0× | n/a |
| Nightingale Health Oyj Class B · OMXHEX:HEALTH | US$77.17M | US$36.79M | n/a | 6.1× | n/a | 1.4× | −335.7% | 0.0× | n/a |
| Seer, Inc. · NASDAQ:SEER | US$75.91M | −US$58.25M | n/a | −4.1× | n/a | 0.4× | −450.9% | 0.1× | 1.03 |
| Selvita SA · GPW:SLV | US$75.22M | US$113.4M | n/a | 1.4× | 9.1× | 1.0× | −0.6% | 0.5× | n/a |
| Sera Prognostics, Inc. · NASDAQ:SERA | US$69.65M | US$28.84M | n/a | 300× | n/a | 1.3× | n/a | 0.1× | 0.57 |
| BioPorto A/S · OMXCOP:BIOPOR | US$68.30M | US$58.06M | 53.8× | 10.7× | n/a | 5.7× | 23.3% | 0.1× | n/a |
| Nanoform Finland Oyj · OMXHEX:NANOFH | US$66.63M | US$52.80M | n/a | 11.9× | n/a | 1.7× | −339.1% | 0.2× | n/a |
| Applied BioCode Corp. · TWSE:6598 | US$64.88M | US$49.53M | n/a | 2.5× | n/a | 3.0× | −7.3% | 0.1× | n/a |
| Median of the others | US$75.56M | US$55.43M | 39.4× | 4.3× | 13.6× | 2.4× | −25.1% | 0.1× | 1.30 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.24 · 2 analysts
- Revenue, year to Dec 2026
- 5.7M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Lishan Aklog | Chairman, Chief Executive Officer |
| Dennis McGrath | Chief Financial Officer |
| Shaun O'Neil | President & Chief Operating Officer |
| Michael Gordon | General Counsel & Corporate Secretary |
| Deepika A. Lakhani | Senior Vice President, Chief Regulatory & Quality Officer |
| Suman M. Verma | Senior Vice President, Chief Scientific Officer |
| Victoria T. Lee | Executive Vice President, Chief Medical Officer |
| Brian deGuzman | Chief Technology & Compliance Officer |
Board
| Director | Role |
|---|---|
| Lishan Aklog | Chairman, Chief Executive Officer |
| Debbie White | |
| Dennis Matheis | Board Member |
| Jacque J. Sokolov | Board Member |
| James L. Cox | Board Member |
| John R. Palumbo | Board Member |
| Ron Sparks | |
| Stanley N. Lapidus | Vice-Chairman |
Events
Calls
| Call | When | Status |
|---|---|---|
| Lucid Diagnostics (NASDAQ:LUCD) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q1 2026 Earnings Call | Thu, May 14, 2026 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q4 2025 Earnings Call | Thu, Mar 26, 2026 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q2 2025 Earnings Call | Wed, Aug 13, 2025 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q1 2025 Earnings Call | Wed, May 14, 2025 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q4 2024 Earnings Call | Mon, Mar 24, 2025 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q2 2024 Earnings Call | Mon, Aug 12, 2024 · 8:30 AM ET | Replay |
All 20 calls
| Call | When | Status |
|---|---|---|
| Lucid Diagnostics (NASDAQ:LUCD) Q1 2024 Earnings Call | Mon, May 13, 2024 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q4 2023 Earnings Call | Tue, Mar 26, 2024 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q3 2023 Earnings Call | Tue, Nov 14, 2023 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q2 2023 Earnings Call | Tue, Aug 15, 2023 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q1 2023 Earnings Call | Tue, May 16, 2023 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q4 2022 Earnings Call | Tue, Mar 14, 2023 · 8:30 AM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q3 2022 Earnings Call | Mon, Nov 14, 2022 · 4:30 PM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q2 2022 Earnings Call | Mon, Aug 15, 2022 · 4:30 PM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q1 2022 Earnings Call | Mon, Apr 04, 2022 · 4:30 PM ET | Replay |
| Lucid Diagnostics (NASDAQ:LUCD) Q4 2021 Earnings Call | Mon, Mar 28, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | +9.2% |
| Q2 2026 | Aug 13, 2026 · Before open | −2.0% |
| Q1 2026 | May 13, 2026 · After close | 0.0% |
| Q4 2025 | Mar 30, 2026 | +2.7% |
| Q3 2025 | Nov 12, 2025 · Before open | +6.7% |
| Q2 2025 | Aug 12, 2025 · After close | −1.6% |
| Q1 2025 | May 13, 2025 · After close | +7.6% |
| Q4 2024 | Mar 24, 2025 | +2.0% |
| Q3 2024 | Nov 12, 2024 · After close | +5.0% |
| Q2 2024 | Aug 12, 2024 · Before open | +6.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +0.6% |
| Q4 2023 | Mar 25, 2024 · After close | −6.6% |
| Q3 2023 | Nov 13, 2023 · After close | +12.1% |
| Q2 2023 | Aug 14, 2023 · After close | +0.3% |
| Q1 2023 | May 15, 2023 · After close | +0.7% |
| Q4 2022 | Mar 13, 2023 · After close | +6.8% |
| Q3 2022 | Nov 14, 2022 · After close | −11.9% |
| Q2 2022 | Aug 15, 2022 · After close | −2.1% |
| Q1 2022 | May 11, 2022 · After close | +5.9% |
| Q4 2021 | Mar 28, 2022 · After close | +6.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 15 slides | Nov 12, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 12 slides | Aug 13, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 28 slides | May 14, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 13 slides | Mar 26, 2026 |
| Q1 2025 Earnings Presentation | Earnings | 14 slides | May 14, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 16 slides | Mar 24, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 20 slides | Nov 13, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 22 slides | Aug 12, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 22 slides | May 13, 2024 |
| Q4 2023 Earnings Presentation | Earnings | 21 slides | Mar 26, 2024 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2023 Earnings Presentation | Earnings | 19 slides | Nov 14, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 19 slides | Aug 15, 2023 |
Financings
| Raise | Date |
|---|---|
| Private placement of series C Convertible Preferred Stock Closed: US$15M raised · US$1,000 a share Buyers: Holders of a majority of the Company's 12.0% senior secured convertible notes due 2029 Use of proceeds: To accelerate near-term commercial operations and for working capital and general corporate purposes | Oct 22, 2026 |
| Registered direct offering of common shares Closed: US$18M raised · US$1 a share · Canaccord Genuity LLC +1 Dealers: Canaccord Genuity LLC (co-lead), BTIG, LLC (co-lead) Buyers: fundamental institutional investor ($15 million investment) Use of proceeds: Working capital and general corporate purposes | Apr 24, 2026 |
| Public offering of common stock Closed: US$26.9M raised · US$1 a share · Canaccord Genuity LLC +2 Dealers: Canaccord Genuity LLC (co-lead), BTIG, LLC (co-lead), Maxim Group LLC Use of proceeds: Working capital and general corporate purposes | Sep 11, 2025 |
| Public offering of common stock Closed: US$16.1M raised | May 14, 2025 |
| Registered direct offering of shares of common stock Closed: US$15.3M raised · US$1.1 a share · Canaccord Genuity Dealers: Canaccord Genuity (lead) Use of proceeds: Working capital and other general corporate purposes | Mar 5, 2025 |
| Five-year convertible notes Closed: US$21.95M raised Use of proceeds: $3.61 million used to retire existing convertible debt; remainder adds cash to extend runway past reimbursement milestones | Dec 3, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$14.00 a share on Oct 13, 2021.
- Price
- US$14.00 a share
- Shares offered
- 5,000,000 shares of common stock
- Offering size
- US$70 million
- Underwriters' option
- Up to 750,000 more shares
- Listing
- LUCD on Nasdaq
- Underwriters
- Cantor, Canaccord Genuity, BTIG, Needham & Company · In the order on the cover
- Shares delivered
- On or about Oct 18, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jan 21, 2020 |
| Filed publicly | Sep 22, 2021 |
| Amended 3 times | Newest Oct 8, 2021 |
| Shares registered with an exchange | Oct 12, 2021 |
| Declared effective by the SEC | Oct 13, 2021 |
| Final prospectus, with the price | Oct 15, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 15, 2021 |
| EFFECT · Notice that a registration is effective | Oct 13, 2021 |
| CERT · Exchange's certificate of listing | Oct 13, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 12, 2021 |
| CORRESP · Letter to the SEC | Oct 12, 2021 |
| S-1/A · Registration statement, amended | Oct 8, 2021 |
| CORRESP · Letter to the SEC | Oct 8, 2021 |
| S-1/A · Registration statement, amended | Oct 7, 2021 |
| CORRESP · Letter to the SEC | Oct 6, 2021 |
| S-1/A · Registration statement, amended | Oct 1, 2021 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Sep 22, 2021 |
| S-1 · Registration statement | Sep 22, 2021 |
| UPLOAD · Letter from the SEC | Sep 15, 2021 |
| DRSLTR · Letter to the SEC with a draft | Sep 3, 2021 |
| DRS/A · Draft registration statement, amended | Sep 3, 2021 |
| UPLOAD · Letter from the SEC | Aug 6, 2021 |
| DRS/A · Draft registration statement, amended | Jul 14, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jul 13, 2021 |
| UPLOAD · Letter from the SEC | Feb 19, 2020 |
| DRS · Draft registration statement | Jan 21, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 15, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.71M | 4.35M | 2.43M | 377.0K | 500.0K | 0 | 0 | |
| Cost of revenue | 6.67M | 7.10M | 8.48M | 100.0M | 585.0K | 0 | ||
| Gross profit | -2.84M | -3.92M | -6.05M | 377.0K | 500.0K | 0 | ||
| Research and development | 5.68M | 5.99M | 7.25M | 11.3M | 9.30M | 5.44M | 3.46M | 715.6K |
| Selling, general and administrative | 23.9B | 20.2B | 19.3M | 23.7M | 21.0K | 7.00K | 958.7K | 615.4K |
| Operating income | -49.6M | -46.1M | -48.5M | -56.3M | -27.4M | -8.28M | -4.42M | -1.13M |
| Depreciation and amortization | 872.0K | 1.17M | 2.50M | 1.94M | 4.00K | 8.28M | 4.42M | 1.69M |
| EBITDA | -48.8M | -44.9M | -46.0M | -54.3M | -27.4M | -1 | 0 | 562.9K |
| Interest expense | 22.0K | 26.0K | 416.0K | 8.00K | 659.0K | 0 | 0 | 0 |
| Income before tax | -58.0M | -45.5M | -52.7M | -56.2M | -28.1M | -8.28M | -4.42M | -1.13M |
| Income tax | 0 | 0 | 2.33M | 1.71M | 659.0K | -8.28M | -4.42M | -1.69M |
| Net income | -58.0M | -45.5M | -52.7M | -56.2M | -28.1M | -8.28M | -4.42M | -1.13M |
| Earnings per share, basic | -0.69 | -1.05 | -1.26 | -1.55 | -1.51 | -0.59 | -0.12 | -0.03 |
| Earnings per share, diluted | -1.05 | -1.26 | -1.55 | -1.51 | -0.59 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 34.7M | 22.4M | 18.9M | 22.5M | 53.7M | 111.0K | 156.4K | 17.8K |
| Short-term investments | 1.33M | 1.12M | 118.0K | 118.1K | ||||
| Receivables | 643.0K | 45.0K | 45.0K | 17.0K | 200.0K | 1 | ||
| Inventory | 353.0K | 341.0K | 278.0K | 111.0K | 493.0K | 834.0K | 0 | |
| Current assets | 37.5M | 25.1M | 22.1M | 24.4M | 57.3M | 1.44M | 390.9K | 17.8K |
| Property, plant and equipment | 809.0K | 1.06M | 1.33M | 1.59M | 971.0K | |||
| Goodwill | 735.3M | |||||||
| Total assets | 40.4M | 30.7M | 27.3M | 32.5M | 59.0M | 2.19M | 1.03M | 17.8K |
| Accounts payable | 970.0K | 1.24M | 1.15M | 1.06M | 1.49M | 2.06M | 799.1K | 497.2K |
| Current liabilities | 28.6M | 23.5M | 29.4M | 8.43M | 4.26M | 15.7M | 6.34M | 1.08M |
| Total debt | 25.8M | 21.3M | 15.3M | 2.00M | 13.3M | |||
| Total liabilities | 29.5M | 25.3M | 29.6M | 9.46M | 4.26M | 15.7M | 6.34M | 1.08M |
| Shareholders' equity | 10.9M | 5.39M | -2.31M | 23.0M | 54.7M | -13.5M | -5.31M | -1.06M |
| Shares outstanding | 131.1M | 63.1M | 42.3M | 40.5M | 34.9M | 14.1M | 37.0M | 37.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -46.5M | -44.1M | -32.8M | -29.7M | -17.7M | -5.63M | -2.36M | -170.6K |
| Capital spending | -197.0K | -296.0K | -221.0K | -3.20M | -862.0K | -862.0K | -4 | -862.0K |
| Free cash flow | -46.7M | -44.4M | -33.0M | -32.9M | -18.5M | -5.63M | -2.36M | -113.7K |
| Cash from investing | -197.0K | -646.0K | -221.0K | -4.11M | -862.0K | -862.0K | -862.0K | -862.0K |
| Cash from financing | 59.0M | 48.2M | 29.5M | 2.61M | 72.1M | 5.58M | 2.50M | 131.5K |
| Share buybacks | 272.0M | 447.0M | 551.0M | 109.0M | ||||
| Change in cash | 12.3M | 3.46M | -3.58M | -31.2M | 53.5M | -45.0K | 138.6K | 17.8K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 8-K · Current report | Oct 22, 2026 | Financing | SEC |
| 8-K · Current report | Oct 16, 2026 | Current report | SEC |
| 8-K · Current report | Sep 22, 2026 | Current report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 3/A · Initial statement of ownership, amended | Apr 24, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 24, 2026 | Current report | SEC |
| 424B5 · Prospectus | Apr 23, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 23, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Apr 20, 2026 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 13, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Apr 2, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Apr 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 27, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Mar 26, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| CORRESP · Letter to the SEC | Mar 25, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Mar 25, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 25, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| S-3 · Registration statement | Dec 5, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 10, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2025 | Management or board change | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| 424B5 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 9, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 424B3 · Prospectus | Jun 3, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 2, 2025 | Other filings | SEC |
| 8-K · Current report | May 30, 2025 | Material contract | SEC |
| 424B5 · Prospectus | May 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 27, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 27, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| S-3 · Registration statement | May 21, 2025 | Offer document | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 11, 2025 | Current report | SEC |
| 424B5 · Prospectus | Apr 10, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Apr 9, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2025 | Current report | SEC |
| 424B5 · Prospectus | Mar 5, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 4, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| 8-K · Current report | Feb 24, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 31, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jan 31, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 12, 2024 | Big-stake notice | SEC |
| D | Dec 6, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 29, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 18, 2024 | Material contract | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jul 23, 2024 | Meeting outcome | SEC |
| 424B3 · Prospectus | Jul 19, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 19, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 15, 2024 | Other filings | SEC |
| S-3/A · Registration statement, amended | Jul 12, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 8, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Jul 8, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 1, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 21, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Jun 6, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Jun 6, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 24, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | May 24, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2024 | Insider trade | SEC |
| 8-K · Current report | May 7, 2024 | Management or board change | SEC |
| 8-K · Current report | May 2, 2024 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 18, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Mar 25, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 14, 2024 | Financing | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 20, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2024 | Financing | SEC |
| 8-K · Current report | Nov 28, 2023 | Current report | SEC |
| 8-K · Current report | Nov 24, 2023 | Current report | SEC |
| 8-K · Current report | Nov 13, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Management or board change | SEC |
| D | Nov 1, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 18, 2023 | Financing | SEC |
| 4 · Change in ownership | Sep 27, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 27, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 26, 2023 | Other filings | SEC |
| 4 · Change in ownership | Sep 22, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jun 21, 2023 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | Jun 2, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Jun 1, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 26, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 26, 2023 | Other filings | SEC |
| S-3 · Registration statement | May 22, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | May 1, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 1, 2023 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 19, 2023 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Apr 13, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 6, 2023 | Insider trade | SEC |
| D | Apr 5, 2023 | Other filings | SEC |
| 8-K · Current report | Apr 3, 2023 | Current report | SEC |
| 8-K · Current report | Mar 24, 2023 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 24, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Mar 23, 2023 | Big-stake notice | SEC |
| D | Mar 22, 2023 | Other filings | SEC |
| 8-K · Current report | Mar 14, 2023 | Results | SEC |
| 10-K · Annual report | Mar 13, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 13, 2023 | Financing | SEC |
| 8-K · Current report | Feb 17, 2023 | Financing | SEC |
| 8-K · Current report | Feb 16, 2023 | Current report | SEC |
| S-8 · Registration statement for employee plans | Feb 10, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 10, 2023 | Offer document | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 18, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 7, 2022 | Other filings | SEC |
| 424B5 · Prospectus | Dec 6, 2022 | Offer document | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 2, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Dec 2, 2022 | Financing | SEC |
| CORRESP · Letter to the SEC | Dec 1, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 1, 2022 | Other filings | SEC |
| S-3 · Registration statement | Nov 23, 2022 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
This page holds 200 of 283 filings. Open Filings
Cap table
Built by 6ix from Lucid Diagnostics Inc.’s releases · as of Nov 10, 2026
- Common shares
- 206,977,800
- Fully diluted
- 206,977,800
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 206,977,800 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 206,977,800 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dennis M. McGrath Other companies: Citius Oncology, Inc. (Director · Since at least Aug 12, 2024); Citius Pharmaceuticals, Inc. (Director · Since at least Feb 7, 2023); PAVmed Inc. (President and CFO · Since at least Feb 14, 2018); DarioHealth Corp. (Board Member · Since at least Oct 23, 2017) | Chief Financial Officer · Since at least Oct 13, 2021 |
| Jacque J. Sokolov Other companies: Medcath Corp (Director · Oct 2, 2006 – Aug 24, 2012 · Past); Hospira Inc (Director · Jun 30, 2006 – Sep 3, 2015 · Past) | Board Member · Since at least Oct 13, 2021 |
| James L. Cox Other companies: Adagio Medical Holdings, Inc (Director · Since at least Jul 31, 2024); PAVmed Inc. (Director · Apr 1, 2021 – Feb 22, 2024 · Past) | Director · Since at least Oct 13, 2021 |
| John Palumbo Other companies: DarioHealth Corp. (Chairman of the Board, Board Member · Since at least Apr 10, 2026); Cencora, Inc. (Director · Apr 13, 2026 – Nov 5, 2026 · Past) | Board Member · Since at least Sep 22, 2025 |
| Lishan Aklog Other companies: PAVmed Inc. (Chairman, Chief Executive Officer · Since at least Jan 29, 2016); Viveon Health Acquisition Corp (Director · Dec 22, 2020 – Dec 23, 2020 · Past) | Chairman, Chief Executive Officer · Since at least Oct 13, 2021 |
| Aster Angagaw Other companies: Accendra Health, Inc. (Director · Mar 1, 2021 – Apr 29, 2021 · Past) | Director · Oct 13, 2021 – Feb 18, 2022 · Past |
| Brian deGuzman Other companies: PAVmed Inc. (Executive Vice President, Chief Technology & Compliance Officer · Since at least Jan 29, 2016) | Chief Technology & Compliance Officer · Since at least Nov 5, 2026 |
| Debra White Other companies: PAVmed Inc. (Director · Since at least Apr 22, 2021) | Director · Since at least Aug 1, 2022 |
| Deepika A. Lakhani Other companies: PAVmed Inc. (Senior Vice President, Chief Regulatory & Quality Officer · Since at least Nov 5, 2026) | Senior Vice President, Chief Regulatory & Quality Officer · Since at least Nov 5, 2026 |
| Dennis Matheis Other companies: DarioHealth Corp. (Board Member · Since at least Jul 2, 2020) | Director · Since at least May 6, 2024 |
All 19 people
| Person | Seat |
|---|---|
| Michael Gordon Other companies: PAVmed Inc. (Executive Vice President, General Counsel & Corporate Secretary · Since at least May 31, 2022) | General Counsel & Corporate Secretary · Since at least May 31, 2022 |
| Ronald M Sparks Other companies: PAVmed Inc. (Director · Since at least Jan 29, 2016) | Director · Since at least Oct 13, 2021 |
| Shaun O'Neil Other companies: PAVmed Inc. (Executive Vice President, Chief Operating Officer · Since at least Feb 22, 2022) | President & Chief Operating Officer · Since at least Mar 18, 2022 |
| Stanley N. Lapidus Other companies: T2 Biosystems, Inc. (Director · Jun 17, 2016 – Jun 11, 2019 · Past) | Vice-Chairman · Since at least Oct 13, 2021 |
| Victoria T. Lee Other companies: PAVmed Inc. (Executive Vice President, Chief Medical Officer · Since at least Dec 9, 2025) | Executive Vice President, Chief Medical Officer · Since at least Mar 23, 2026 |
| David F Wurtman | Chief Medical Officer · Oct 13, 2021 – Oct 13, 2021 · Past |
| Debbie White | Director · Since at least Nov 4, 2026 |
| Ron Sparks | Director · Since at least Nov 4, 2026 |
| Suman M. Verma | Senior Vice President, Chief Scientific Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Lucid Diagnostics Inc.